UBS Group
IMGN

UBS Group’s Immunogen Inc IMGN Stock Holding History

UBS Group’s Portfolio IMGN Stock Details IMGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-201,197
Closed -$5.97M – 10395
2023
Q4 		$5.97M Sell
201,197
-10,983
-5% -$219K ﹤0.01% 2597
2023
Q3 		$3.37M Buy
212,180
+76,249
+56% +$1.27M ﹤0.01% 2950
2023
Q2 		$2.57M Sell
135,931
-410,171
-75% -$4.84M ﹤0.01% 3289
2023
Q1 		$2.1M Sell
546,102
-399,586
-42% -$1.7M ﹤0.01% 3385
2022
Q4 		$4.69M Buy
945,688
+800,497
+551% +$4.34M ﹤0.01% 2563
2022
Q3 		$694K Sell
145,191
-50,996
-26% -$269K ﹤0.01% 4061
2022
Q2 		$883K Sell
196,187
-382,315
-66% -$1.66M ﹤0.01% 3835
2022
Q1 		$2.75M Buy
578,502
+276,405
+91% +$1.53M ﹤0.01% 3126
2021
Q4 		$2.24M Buy
302,097
+283,972
+1,567% +$1.76M ﹤0.01% 3628
2021
Q3 		$103K Sell
18,125
-48,227
-73% -$279K ﹤0.01% 5813
2021
Q2 		$437K Sell
66,352
-164,191
-71% -$1.15M ﹤0.01% 4834
2021
Q1 		$1.87M Buy
230,543
+214,523
+1,339% +$1.75M ﹤0.01% 3632
2020
Q4 		$103K Sell
16,020
-552
-3% -$3.22K ﹤0.01% 5672
2020
Q3 		$60K Sell
16,572
-18,671
-53% -$75.4K ﹤0.01% 5513
2020
Q2 		$162K Sell
35,243
-88,372
-71% -$376K ﹤0.01% 4951
2020
Q1 		$422K Sell
123,615
-87,687
-41% -$383K ﹤0.01% 4123
2019
Q4 		$1.08M Sell
211,302
-225,311
-52% -$765K ﹤0.01% 4140
2019
Q3 		$1.06M Buy
436,613
+347,353
+389% +$922K ﹤0.01% 3920
2019
Q2 		$194K Sell
89,260
-36,990
-29% -$87.5K ﹤0.01% 4935
2019
Q1 		$342K Sell
126,250
-224,559
-64% -$973K ﹤0.01% 4299
2018
Q4 		$1.68M Buy
350,809
+184,822
+111% +$1.12M ﹤0.01% 3203
2018
Q3 		$1.57M Buy
165,987
+67,131
+68% +$645K ﹤0.01% 3432
2018
Q2 		$962K Sell
98,856
-377,467
-79% -$3.98M ﹤0.01% 3808
2018
Q1 		$5.01M Buy
476,323
+371,886
+356% +$3.67M ﹤0.01% 2306
2017
Q4 		$670K Sell
104,437
-8,009
-7% -$49.4K ﹤0.01% 4085
2017
Q3 		$860K Sell
112,446
-11,418
-9% -$75.9K ﹤0.01% 3827
2017
Q2 		$881K Buy
123,864
+23,897
+24% +$109K ﹤0.01% 3726
2017
Q1 		$387K Sell
99,967
-13,077
-12% -$38.2K ﹤0.01% 4223
2016
Q4 		$231K Buy
113,044
+16,223
+17% +$32.6K ﹤0.01% 4695
2016
Q3 		$259K Sell
96,821
-41,785
-30% -$122K ﹤0.01% 4367
2016
Q2 		$427K Buy
138,606
+71,613
+107% +$449K ﹤0.01% 4008
2016
Q1 		$571K Sell
66,993
-113,789
-63% -$963K ﹤0.01% 3677
2015
Q4 		$2.45M Buy
180,782
+127,029
+236% +$1.56M ﹤0.01% 2609
2015
Q3 		$516K Buy
53,753
+2,834
+6% +$41.4K ﹤0.01% 3873
2015
Q2 		$732K Sell
50,919
-7,973
-14% -$87.6K ﹤0.01% 3816
2015
Q1 		$527K Buy
58,892
+3,008
+5% +$21.8K ﹤0.01% 4103
2014
Q4 		$341K Buy
+55,884
New +$511K ﹤0.01% 4552

Other funds holding IMGN

IA
IFP Advisors Tampa, Florida $4.82B AUM 20.19% 1-Year Est. Return
MG
Mather Group Chicago, Illinois $10B AUM 15.14% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

UBS Group's IMGN Position: Q1 2024 in Review

UBS Group sold out of Immunogen Inc (IMGN) in Q1 2024, closing a stake of 201,197 shares — an estimated $5.97M sold.

UBS Group first reported a position in IMGN in Q4 2014 and held it in 37 quarters. The position peaked at $5.97M in Q4 2023. 3 funds tracked by Wall St. Rank hold IMGN as of Q1 2024.

  • UBS Group reported no remaining Immunogen Inc position as of Q1 2024 after selling out during the quarter.
  • UBS Group sold 201,197 Immunogen Inc shares in Q1 2024, an estimated $5.97M.
  • UBS Group first reported a position in Immunogen Inc in Q4 2014 and held it in 37 quarters.
  • UBS Group's Immunogen Inc position peaked at $5.97M in Q4 2023.
  • 3 funds tracked by Wall St. Rank held Immunogen Inc as of Q1 2024.

Based on UBS Group's 13F filing for Q1 2024, filed 13 May 2024.